CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia - sprookjes - yvandenbroek - TriplyDB

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q28084879

about

Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Novel immunotherapies in lymphoid malignancies Cancer-treatment-induced neurotoxicity--focus on newer treatments High-content molecular profiling of T-cell therapy in oncology P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications Future prospects of therapeutic clinical trials in acute myeloid leukemia.T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Immunotherapy in hematologic malignancies: past, present, and future.CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.Landscape of Tumor Antigens in T Cell Immunotherapy.A Flow-Through Cell Electroporation Device for Rapidly and Efficiently Transfecting Massive Amounts of Cells in vitro and ex vivo Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy.Paving the road ahead for CD19 CAR T-cell therapy Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells Chimeric antigen receptor-modified T cells strike back.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Chimeric antigen receptor-redirected T cells return to the bench The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports.BCR/ABL can promote CD19+ cell growth but not render them long-term stemness.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?Therapies on the horizon for childhood acute lymphoblastic leukemia.CAR T-cell immunotherapy: The path from the by-road to the freeway?Immunotherapy and targeted therapy for cervical cancer: an update.CAR T-cells merge into the fast lane of cancer care.

P2860

Q26741977-F7733B1A-FBEE-49A7-B63C-0D6B4919E0E4 Q26749560-4F8DB19B-00E9-42F4-BC64-B6413A21ACBB Q26773309-B4E26702-328C-4041-91CD-DE77046C289C Q26777394-5E49600C-6046-4DD0-A204-E979639BA73A Q26782604-890BCD74-BBA9-416B-A314-CA20715CC5A2 Q28066792-AB861825-D0BF-436D-A3F8-82708F648EBA Q28078609-344EEA8E-2C7C-4A44-B587-206EA8B56AFE Q28079823-4B225208-FF54-4271-B93B-74E20314272E Q30244168-05F02431-47E2-4EEA-8D01-E6368FBEF789 Q30251555-3C5FB147-E368-4471-8889-F9F8237858A4 Q33433407-3F13CB58-CFF2-4F35-8239-16A097C6418C Q33593865-8782E8B4-E73A-45E5-AC74-73C9E4D3CA51 Q33655754-2D77E562-B443-410D-817E-7D88422CA734 Q33698398-928D4F4E-A309-4C65-B1F1-501069A57A4D Q33757149-BB7F32E2-2DAF-419B-A413-586B8B4F7873 Q33851168-E8CAC3C7-4D02-44E8-B572-EC99900B7E9C Q34048101-B24F875B-446C-4ECD-827F-3475CD8306CD Q35877585-7F7EE697-C5AE-4393-9F03-AE1214ECCD92 Q36173272-40A8BB51-5C19-4AB3-B2F9-4A15C2EE35C6 Q36307736-52CDEC75-9604-4317-88F9-8DA84B1E3373 Q36427925-9A714C41-82AC-4953-90CB-48DF94C84CE1 Q36430742-DFB4AA24-7B37-4BBD-A76C-F256AC20399C Q36479385-B72A2405-9E6A-4317-A255-4DF3774A68E2 Q36777093-68A32EF9-0F02-4BD5-BF60-FA04934EDD28 Q36963057-B92592A0-5D9D-429A-9127-366FD1717F05 Q37040370-B5471B0B-A5A9-46BE-824E-192AC4CED7D4 Q37058110-489D43E6-981A-4C8B-B02F-59F59A280B90 Q37141503-49B27770-8CC9-4C4C-898A-AD6E9CACD938 Q37301510-8430B535-6221-408F-A56B-35EFF2C38FA8 Q37516448-864D41A0-E1C1-498A-8ED2-EC0802630A06 Q37517482-492BEAFD-10E4-4FEB-8137-9D747AB60115 Q37530579-A5A74ECB-C6D1-4A70-B851-B6CD720B3A41 Q37531026-043B0BFA-8F8E-4AA9-8514-4105275E445A Q37555940-7DED60AD-AE3D-416B-A386-082BCEAD4DBC Q37615772-D69A2FA3-52B3-4A71-BEDC-F5F77456153F Q37625303-FD02C25C-9FFE-4256-971D-4A406E033FBA Q38504437-BFCCBC85-8B31-4E65-A2B5-03157D5A43CF Q38632105-5434D784-A978-4A0F-A984-968A1A4D7398 Q38633525-4F2C13F1-52FA-4D99-96BE-65044954C7D2 Q38635027-6D3FFC53-FEB7-4B8F-819C-D81C5FBEB498

P2860

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q28084879

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@ast

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@en

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@nl

type

label

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@ast

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@en

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@nl

prefLabel

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@ast

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@en

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@nl

P1433

Q28084879-01996EEF-567D-4A8B-B5CC-DE08A5BDF015

P1476

Q28084879-A5463D8B-0F64-4CD9-996B-32DC63A199F8

P2093

Q28084879-561ED278-910B-4126-A370-F868BA7893FC

Q28084879-5702BF92-9983-412B-87BE-C1A5494035CE

Q28084879-FA0A1002-4F78-4840-9496-9186E51C6522

P2860

Q28084879-08E19B9C-BCB1-4128-B764-CB7D112301D6

Q28084879-0CEFEFB2-D28D-4F52-8EBE-0917431F0BAD

Q28084879-0D2D25A8-CEBF-4EC4-85B2-31454B9B4194

Q28084879-1066081B-D716-4ADE-B30E-2805BB42B149

Q28084879-10680975-B4DC-4A37-B5A5-0DFD0F34C008

Q28084879-14842184-1BFC-45A0-822B-B5C82A5763C6

Q28084879-1A91A7B9-13D4-457F-8A32-94C54A5CDBB4

Q28084879-1AF086C3-1083-44AD-83CE-B66FD42996BB

Q28084879-211FA017-6976-44C0-A0AE-7DBFC0D3E8D2

Q28084879-23CA0B66-0642-4C65-B094-A98B7ABADA3B

P304

Q28084879-003E8644-86A4-4C24-9D4E-8EE4B6C36258

P31

Q28084879-52A4B8E7-31C0-4CC6-AF8B-8AA495A86469

P3181

Q28084879-D66F5449-78DE-47B2-91A0-6508AC652568

P356

Q28084879-EA61E344-83FA-4333-A10C-7E50F7565115

P407

Q28084879-FA67CA06-3B84-43AA-8914-130D0C0C939B

P433

Q28084879-083B691D-F9B2-4227-8337-C39375D46867

P478

Q28084879-FE5B3583-F499-4AA9-952D-37908D4ABA88

P50

Q28084879-64C194A9-1DD5-4DE4-907C-40D06AE2D131

P577

Q28084879-C8DD953D-9598-4E78-ADC4-3D0C2345E591

P5875

Q28084879-FF9BB607-A126-42F5-8902-530189E4119B

P698

Q28084879-0549B448-02A7-4C2F-80D7-697A3FF2B5C3

P921

Q28084879-0733BDAC-3300-4809-A3D4-100E3A4AA9FE

P932

Q28084879-AD2AD64B-46CD-4442-B8BB-361493576B4D

P3181

P356

BLOOD-2014-12-580068

P1433

P1476

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

@en

P2093

David L Porter

http://www.w3.org/2001/XMLSchema#string

Shannon L Maude

http://www.w3.org/2001/XMLSchema#string

Stephan A Grupp

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Chimeric antigen receptor therapy for cancer

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

P304

4017-4023

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2570922

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2014-12-580068

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

David T Teachey

P577

2015-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277080564

http://www.w3.org/2001/XMLSchema#string

P698

25999455

http://www.w3.org/2001/XMLSchema#string

P921

P932

4481592

http://www.w3.org/2001/XMLSchema#string